First approved in 2010 for treatment of metastatic melanoma, immune checkpoint inhibitors (ICIs) are now approved for more than 17 cancer types, and it is estimated that 1 in 3 patients with cancer now qualify for ICIs.1 ICIs remove key regulators of T-cell function to unleash antitumor effects, but T-cell disinhibition can also cause immune-related adverse events in up to 60%-85% of patients.2 Though the epidemiology of ICI-induced acute kidney injury has been well characterized,3-5 there is extremely limited data on the long-term toxicities of ICIs.